China-based CAR-T company Oricell raises $40M more as it looks to go public
manbetx3.0 CAR-T公司奥利赛尔再筹集4000万美元，寻求上市

Oricell Therapeutics has raised more than $110 million in what it calls a pre-IPO financing. The company is developing CAR-T therapies for solid tumors, including a GPC3-targeted autologous CAR-T therapy for a type of liver cancer.
奥利赛尔(Oricell Therapeutics)宣布完成其称之为“Pre-IPO”轮的融资，金额超过1.1亿美元。该公司正开发用于实体瘤的CAR-T疗法，包括一款用于治疗某类肝癌的GPC3靶向自体CAR-T疗法。